New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease | Biogen – Biogen October 25, 2023
Eisai, Biogen receives U.S. FDA approval for Alzheimer’s drug, applies for full approval January 7, 2023
Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer’s drug December 30, 2022December 30, 2022
House investigation faults FDA, Biogen for Alzheimer’s drug approval December 29, 2022December 29, 2022
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen – The New York Times December 29, 2022
What increasing hope for Biogen Alzheimer’s drug means for Eli Lilly December 1, 2022November 30, 2022
Eisai, Biogen say Alzheimer’s drug succeeds in slowing cognitive decline September 28, 2022September 28, 2022
FDA offers Biogen, Eisai a shortcut to a possible lecanemab approval – Endpoints News July 6, 2022July 6, 2022
Dow Jones Futures: Market Rallies On Powell Comments; Apple, Nvidia, Tesla In Focus; Biogen Dives Late January 12, 2022January 12, 2022